MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Diarrhea, unspecified (R19.7)

HealthDay 17 June at 10.40 PM

CDC Warns of Salmonella Danger Posed by Pet Bearded Dragons

In a health advisory issued Friday, the U.S. Centers for Disease Control and Prevention warned of a Salmonella outbreak linked to pet bearded dragons, noting that there have been reports of 15 illnesses across nine states."Four people have been hospitalized," the agency said, although no deaths linked to the scaly pets have been reporte

HealthDay 17 June at 03.58 PM

Survodutide Tied to Significant Improvement in Fatty Liver Disease

Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, according to a phase 2 study published online June 7 in the New England Journal of Medicine to

Evalytics 19 March at 06.08 AM

FDA approves first drug for common form of liver inflammation

The FDA has approved the first-ever medication for nonalcoholic steatohepatitis (NASH), a common form of liver inflammation linked to obesity, type 2 diabetes, and other metabolic conditions. NASH, characterized by liver inflammation due to excess fat accumulation, affects an estimated 6 to 8 million people in the US with moderate to advanced fibrosis.

Evalytics 26 February at 09.07 PM

Norovirus spreading in the Northeast, CDC data shows

The CDC warns of norovirus outbreak in the Northeastern U.S. Symptoms include vomiting, diarrhea, and stomach cramps. Health officials emphasize handwashing and disinfection to prevent spread.

HealthDay 05 January at 04.32 PM

Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer

For patients with metastatic, persistent, or recurrent cervical cancer, adding atezolizumab to a standard bevacizumab plus platinum regimen significantly improves progression-free and overall survival, according to a study published in the January issue of The Lancet.Ana Oaknin, M.D., from the Vall d'Hebron Institute of Oncology in Barce

HealthDay 05 January at 12.12 PM

Tejocote Supplements Sold Online at Amazon, Etsy May Contain Fatal Poison: FDA

Tejocote weight-loss supplements sold online through Amazon or Etsy could contain a highly toxic substance, the U.S. Food and Drug Administration is warning.FDA tests revealed that capsules labeled as tejocote instead contained yellow oleander, a poisonous plant native to Mexico and Central America.The FDA found yellow oleander in nine dif

HealthDay 22 December at 04.43 PM

FDA Warns of Counterfeit Ozempic

The U.S. Food and Drug Administration has uncovered counterfeit Ozempic shots in the legitimate U.S. drug supply chain, and is warning patients to be on their guard.The FDA said Thursday that it has <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-cha

HealthDay 06 December at 10.55 PM

Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available

Eli Lilly has announced that its newly approved weight-loss medication, Zepbound, is now available for patients to take."Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound," Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news rel

HealthDay 13 November at 11.56 PM

FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura

The U.S. Food and Drug Administration has approved Adzynma, the first recombinant protein product indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).Adzynma is a purified recombinant form of the ADAMTS13 enzyme that enhances the low l

HealthDay 07 November at 11.50 PM

FDA Approves Voquezna for Erosive Esophagitis, GERD

The U.S. Food and Drug Administration has approved Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal reflux disease (GERD).The approval is based on the results of the PHALCON-EE phase 3 trial, in which Voquezna 20 mg met the prim